"Groundbreaking Parvo Treatment Set to Transform Puppy Care"

Elanco Animal Health has developed the first-ever targeted treatment for canine parvovirus, a highly contagious and deadly virus that affects dogs, especially puppies. The Canine Parvovirus Monoclonal Antibody treatment directly targets the virus, blocking its entry into host cells and resolving symptoms faster. In clinical trials, no dogs treated with the antibody died, and the treatment shortened the course of the disease, increasing survivability. The treatment is administered intravenously in a single dose and is expected to receive full USDA approval in 2024. Clinics using the treatment have reported increased success rates and shorter hospital stays for parvovirus patients.